Abstract:Background: Mutations in low-density lipoprotein (LDL) receptor (LDLR) are one of the main causes of familial hypercholesterolemia, which induces atherosclerosis and has a high lifetime risk of cardiovascular disease. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system is an effective tool for gene editing to correct gene mutations and thus to ameliorate disease. Methods: The goal of this work was to determine whether in vivo somatic cell gene editing through the CRISPR/Cas9 system delivered by adeno-associated virus (AAV) could treat familial hypercholesterolemia caused by the Ldlr mutant in a mouse model. We generated a nonsense point mutation mouse line, Ldlr(E208X), based on a relevant familial hypercholesterolemia-related gene mutation. The AAV-CRISPR/Cas9 was designed to correct the point mutation in the Ldlr gene in hepatocytes and was delivered subcutaneously into Ldlr(E208X) mice. Results: We found that homogeneous Ldlr(E208X) mice (n=6) exhibited severe atherosclerotic phenotypes after a high-fat diet regimen and that the Ldlr mutation was corrected in a subset of hepatocytes after AAV-CRISPR/Cas9 treatment, with LDLR protein expression partially restored (n=6). Compared with the control groups (n=6 each group), the AAV-CRISPR/Cas9 with targeted single guide RNA group (n=6) had significant reductions in total cholesterol, total triglycerides, and LDL cholesterol in the serum, whereas the aorta had smaller atherosclerotic plaques and a lower degree of macrophage infiltration. Conclusions: Our work shows that in vivo AAV-CRISPR/Cas9-mediated Ldlr gene correction can partially rescue LDLR expression and effectively ameliorate atherosclerosis phenotypes in Ldlr mutants, providing a potential therapeutic approach for the treatment of patients with familial hypercholesterolemia.

CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice

CRISPR/Cas9‐mediated Somatic Correction of a Novel Coagulator Factor IX Gene Mutation Ameliorates Hemophilia in Mouse

CRISPR/Cas9-mediated Somatic and Germline Gene Correction to Restore Hemostasis in Hemophilia B Mice

CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A

CRISPR-Cas9-Mediated in Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice.

Gene Therapy for Hemophilia B in Immature Mice Using ScAAV-DJ/8-LP1-hFIXco Vector

Curing hemophilia A by NHEJ-mediated ectopic F8 insertion in the mouse

Low-dose AAV-CRISPR-mediated Liver-Specific Knock-in Restored Hemostasis in Neonatal Hemophilia B Mice with Subtle Antibody Response

In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia

AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B

Delivery of Cas9-guided ABE8e into stem cells using poly(l-lysine) polypeptides for correction of the hemophilia-associated FIX missense mutation

CRISPR/Cas9 Edition of the F9 Gene in Human Mesenchymal Stem Cells for Hemophilia B Therapy

Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion

Paired CRISPR/Cas9 Nickases Mediate Efficient Site-Specific Integration of F9 into rDNA Locus of Mouse ESCs

Ssodn-Mediated In-Frame Deletion with CRISPR/Cas9 Restores FVIII Function in Hemophilia A-Patient-Derived Ipscs and ECs

[Advances in AAV-CRISPR/Cas9-Mediated Hemophilia A Gene Therapy --Review]

Modulation of Immune Reaction in Hydrodynamic Gene Therapy for Hemophilia A.

In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy

Gene Therapy for Hemophilia B Mice with Scaav8-Lp1-hfix

Long-term correction of haemophilia B through CRISPR/Cas9 induced homology-independent targeted integration

Targeted genome engineering based on CRISPR/Cas9 system to enhance FVIII expression in vitro